Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
buprenorphine
Indivior Pty Ltd
Hepatitis C, Chronic
1 trial -
buprenorphine
Indivior Pty Ltd
Opiate-related Disorders
1 trial -
buprenorphine/naloxone
BICYCLE THERAPEUTICS
Opioid Use Disorder
1 trial -
buprenorphine/naloxone
BRIGHT MINDS BIOSCIENCES INC.
Opioid Use Disorder
3 trials -
bupropion SR
BRIGHT MINDS BIOSCIENCES INC.
Tobacco-Use Disorder
1 trial -
butylphthalide(NBP)
The First People's Hospital of Lianyungang
Acute Ischemic Stroke
1 trial -
cagrilintide, Placebo + Placebo, semaglutide, cagrilintide, cagrilintide semaglutide, semaglutide, semaglutide, semaglutide, cagrilintide semaglutide, semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide, cagrilintide
NovoThirteen
Obesity and T2D
1 trial -
carbidopa, levodopa, entacapone
Novartis Pharmaceuticals
Parkinson's Disease
1 trial -
combination NRT
BRIGHT MINDS BIOSCIENCES INC.
Smoking Cessation
1 trial -
combined fixed dose combination
United Therapeutics Europe Ltd
Tuberculosis
1 trial -
combined fixed dose combination
Gain Therapeutics
Tuberculosis
1 trial -
conbercept
Hospital Authority, Hong Kong
Polypoidal Choroidal Vasculopathy
1 trial -
counseling
BRIGHT MINDS BIOSCIENCES INC.
Amphetamine-Related Disorders
1 trial -
counseling
BRIGHT MINDS BIOSCIENCES INC.
Substance-Related Disorders
1 trial -
crizotinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Systemic Anaplastic Large-Cell Lymphoma
1 trial -
cyclosporine or tacrolimus
Wyeth is now a wholly owned subsidiary of Pfizer
Graft Rejection
1 trial -
dabrafenib
Novartis Pharmaceuticals
Melanoma
1 trial -
dapagliflozin
The First People's Hospital of Lianyungang
Diabetic Kidney Disease
1 trial -
diclofenac sodium topical gel
Teva Pharma GmbH
Multiple Sclerosis
1 trial -
docetaxel
Hoffmann-La Roche
Breast Cancer
2 trials -
doxazosin plus tolterodine SR
Samsung Bioepis NL B.V.
Overactive Bladder
1 trial -
dupilumab
Regeneron UK Limited
Chronic Obstructive Pulmonary Disease (COPD)
1 trial -
dupilumab
Regeneron UK Limited
Severe Atopic Dermatitis (AD)
1 trial -
early standardised rhythm control
Rhythm Pharmaceuticals Netherlands B.V.
Atrial Fibrillation
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources